Sensitivity to Intravenous Nicotine: Genetic Moderators
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including the ratings of "good effects" and "drug liking". We hypothesize that smokers with the AG/GG genotype for the OPRM1 A118G will have attenuated subjective-rewarding effects from IV nicotine when compared to those with AA genotype.
| Condition | Intervention | Phase |
|---|---|---|
|
Influence of OPRM1 A118G Status on Subjective Responses to IV Nicotine. |
Drug: Nicotine |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention |
| Official Title: | Sensitivity to Intravenous Nicotine: Genetic Moderators |
- primary hypotheses will test the influence of OPRM1 A118G status on subjective responses to IV nicotine, which will be measured with the drug effects questionnaire (DEQ). [ Time Frame: Injections 30 minutes apart ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 20 |
| Study Start Date: | June 2009 |
| Estimated Study Completion Date: | February 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Nicotine
Intravenous Nicotine
|
Drug: Nicotine
Maximum doses of nicotine 2mg
Other Name: Nicotine
|
Detailed Description:
Increasing evidence suggest that MOR contribute to nicotine's rewarding effect. Further, the functional OPRM1 A118G variant has been linked to rewarding effects of alcohol in alcohol users and to nicotine in female smokers. Since no previous studies examined the influence of the A118G variation on pure nicotine responses, the next logical step is to evaluate how this genetic polymorphism affects nicotine's rewarding, cognitive, and physiological effects using IV nicotine administration in male and female smokers. In addition, the association of the G398A polymorphism of the CHRNA5 gene (rs16969968) with maximal response to nicotinic agonists justifies examination of this SNP as a moderator of IV nicotine sensitivity in humans (Bierut et al. 2008). This SNP will be examined in an exploratory fashion since it is not feasible to fully stratify the study sample for multiple SNPs. The frequency of rs16969968 SNP ranges from 35%-42% among those of European ancestry, making it feasible to examine this variation in our subject sample.
Currently this study is active and enrollment is continuing. Currently there are 158 completers and on going.(Feb 2013)
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Female and male smokers, aged 18 to 50 years;
- History of smoking daily for the past 12 months, 10-25 cigarettes daily;
- Not seeking treatment at the time of the study for nicotine dependence;
- Have a FTND score of at least 5 and CO level > 10ppm;
- In good health as verified by medical history, screening examination, and screening laboratory tests;
- For women, not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods.
Exclusion Criteria:
- History of major medical illnesses that the physician investigator deems as contraindicated for the patient to be in the study;
- Regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent psychiatric diagnosis and treatment for Axis I disorders including major depression, bipolar affective disorder, schizophrenia or panic disorder;
- Abuse of alcohol or any other recreational or prescription drugs.
Contacts and Locations| Contact: Lance Barnes | 203-937-4823 | lance.barnes@yale.edu |
| Contact: Stacy Minnix, BSW | 203-937-4805 | stacy.minnix@yale.edu |
| United States, Connecticut | |
| Department of Veterans Affairs | Recruiting |
| West Haven, Connecticut, United States, 06516 | |
| Contact: Mehmet Sofuoglu, M.D., Ph.D. 203-937-4809 mehmet.sofuoglu@yale.edu | |
| Contact: Joel Gelernter, M.D. 932-5711 ext 3590 joel.gelernter@yale.edu | |
| Principal Investigator: Mehmet Sofuoglu, M.D., Ph.D. | |
| Principal Investigator: | Mehmet Sofuoglu, M.D,Ph.D. | Yale University |
More Information
No publications provided
| Responsible Party: | Mehmet Sofuoglu, Principle Investigator, Yale University |
| ClinicalTrials.gov Identifier: | NCT00969137 History of Changes |
| Other Study ID Numbers: | 0905005103, R03DA027474, DCNBR / CNB |
| Study First Received: | August 31, 2009 |
| Last Updated: | February 1, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Nicotine Nicotine polacrilex Ganglionic Stimulants Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Nicotinic Agonists |
Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Central Nervous System Stimulants Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013